drugset / Trial / NCT00619502
Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This is a follow-up of Study A3L10 (NCT00315055) Immunogenicity * To describe the antibody persistence following a primary series vaccination of either DTaP-IPV-HB-PRP\~T or PENTAXIM™ and ENGERIX B®. * To describe the immunogenicity of a booster dose of DTaP-IPV-HB-PRP\~T. Safety \- To describe the safety profile after a booster dose of DTaP-IPV-HB-PRP\~T.
Timeline
- Start
- 2007-12
- Primary completion
- 2008-07
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DTaP-IPV-HB-PRP~T | Vaccine | 0.5 ml | Intramuscular |